Latest News and Press Releases

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. ...

COMMUNIQUÉ DE PRESSE DE NOUVELLES RECHERCHES MONTRENT QUE LE MASITINIB LIMITE LES DOMMAGES NEURONAUX DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE D'ORIGINE NEUROIMMUNE C'EST LA PREMIÈRE FOIS QUE LE...

PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM...

Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...

The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space TEL AVIV, Israel, Oct. 03, 2023 ...

Bredis Healthcare secures KRW 1.7 billion grant for advancing Alzheimer’s disease diagnosis from South Korean government’s Deep Tech TIPS programNovel platform has demonstrated detection of...

TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and...

Tel-Aviv, June 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...

COMMUNIQUE DE PRESSE PUBLICATION DE L'ETUDE CLINIQUE PIVOT DE PHASE 3 AVEC LE MASITINIB DANS LA MALADIE D'ALZHEIMER DANS LA REVUE ALZHEIMER'S RESEARCH & THERAPY Paris, 28 février 2023, 8h AB...

PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN ALZHEIMER'S DISEASE IN THE JOURNAL ALZHEIMER'S RESEARCH & THERAPY Paris, 28 February, 2023, 8am CET ...